Document is current
Any future updates will be listed below
-
Authors
Mease, Philip J. https://orcid.org/0000-0002-6620-0457
Ferrante, Shannon A.
Shiff, Natalie J. https://orcid.org/0000-0002-7410-9709
Fitzgerald, Timothy P. https://orcid.org/0000-0003-3441-1708
Chakravarty, Soumya D. https://orcid.org/0000-0001-7957-838X
Walsh, Jessica A. https://orcid.org/0000-0002-4563-0845
-
Funding
Funding for this research was provided by:
Janssen Scientific Affairs
- License Information
-
More Information
Article History
Received: 15 August 2024
Accepted: 18 October 2024
First Online: 2 December 2024
Declarations
:
: Philip J Mease has received consulting fees from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Eli Lilly, Immagene, Janssen, Novartis, Pfizer, UCB, and Ventyx; speaker fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; and research grants from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, and UCB. Shannon A Ferrante, Natalie J Shiff, Timothy P Fitzgerald, and Soumya D Chakravarty are or were employees of Janssen Scientific Affairs, LLC, a Johnson & Johnson company at the time this work was performed and own stock in Johnson & Johnson. Natalie J Shiff also owns stock in or has owned stock in AbbVie, Gilead, Iovance, Novo-Nordisk, and Pfizer within the past 3 years and is currently an employee of Alpine Immune Sciences, A Vertex Company. Jessica A Walsh has received consulting fees for AbbVie, Eli Lilly, Janssen, Novartis, and UCB; and research funding from AbbVie, Merck, and Pfizer.
: The IQVIA PharMetrics® Plus database, used under license for this study, complies with Health Insurance Portability and Accountability Act (HIPAA) regulations. The data obtained from these analyses were de-identified; thus, no Institutional Review Board approval was required.
